Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus.

Abstract

Dipeptidyl peptidase 4 (DPP4) inhibitors have been widely used in the treatment of type 2 diabetes mellitus. It is well known that DPP4 inhibitors exert their antidiabetes effects mainly by inhibiting the enzymatic degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. The anti-inflammatory effect of DPP4 inhibitors was proved by preclinical and clinical studies of type 2 diabetes and coronary artery disease. Preclinical data using DPP4 inhibitors-based therapies in studies of nonobese diabetic mice demonstrated additional effects, including immunomodulation, preserving beta-cell mass, promoting beta-cell regeneration and reversing newly diagnosed diabetes. Thus, these data show that DPP4 inhibitors may be effective for type 1 diabetes mellitus. However, their potential clinical benefits for type 1 diabetes remain to be evaluated. This paper will provide an overview of the progress of the anti-inflammatory and immunomodulatory effects of DPP4 inhibitors in treating both type 1 and type 2 diabetes.

• Authors: Lin Yang, Jiao Yuan, Zhiguang Zhou
• Journal: Canadian journal of diabetes (Can J Diabetes) Vol. 38 Issue 6 Pg. 473-9 (Dec 2014) ISSN: 2352-3840 [Electronic] Canada
• PMID: 25034244 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2014 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.

Chemical References

• Anti-Inflammatory Agents
• Dipeptidyl-Peptidase IV Inhibitors
• Immunologic Factors

Topics

• Animals
• Anti-Inflammatory Agents (pharmacology)
• Biomedical Research
• Cell Line
• Diabetes Mellitus, Type 1 (drug therapy, physiopathology)
• Diabetes Mellitus, Type 2 (drug therapy, physiopathology)
• Dipeptidyl-Peptidase IV Inhibitors (pharmacology)
• Humans
• Immunologic Factors (pharmacology)